https://pubmed.ncbi.nlm.nih.gov/29768174/
HIV-1 vaccine development has been stymied by an inability to induce broadly reactive neutralizing antibodies to the envelope (Env) trimer, the sole viral...
b cellhivvaccinesbasedantibody
https://pubmed.ncbi.nlm.nih.gov/14746526/
An increasing body of evidence suggests that a vaccine that elicits anti-HIV-1 cellular immunity could provide the basis for an effective AIDS vaccine....
recentadvancesdevelopmenthivvaccines
https://asm.org/podcasts/mtm/episodes/hiv-vaccines-with-dan-barouch-mtm-102
Dan Barouch lays out the unique challenges of HIV vaccine development and discusses the ongoing clinical trial with a vaccine developed in his lab.
hiv vaccinesdan barouchasmorg
https://www.sciencedaily.com/releases/2015/06/150604162634.htm
Researchers have identified a molecule that recognizes HIV and initiates an immune response. The findings could help improve the efficacy of HIV vaccines to...
new approachhiv vaccinesresearchoffersimproving
https://www.mdpi.com/2076-393X/10/9/1569
Background: The immunogenicity and safety of COVID-19 vaccines among people living with human immunodeficiency virus (PLWH) are unclear.
immunogenicitysafetycovidvaccinesamong
https://www.nature.com/articles/d41586-025-02439-4?error=cookies_not_supported&code=8635adb9-5aa0-47e4-908e-cdd8fc8e132f
Aug 1, 2025 - Results from early-stage trial show that 80% of participants who received one of two HIV vaccine candidates produced antibodies against viral proteins.
mrna vaccinesimmune responsehivtriggerstrong